Skip to main content
. 2023 Dec 21;8(4):867–877. doi: 10.1182/bloodadvances.2023010648

Figure 1.

Figure 1.

Waterfall plot of best percentage change from baseline in patients with R/R MZL receiving parsaclisib treatment. Best percentage change from baseline in either target lesions for patients with measurable disease at baseline and at least 1 valid postbaseline measurement (blue bars, n = 71) or enlarged portion of spleen for patients with splenomegaly only at baseline and at least 1 valid postbaseline measurement of spleen (red bars, n = 10) by IRC (cohort 2 WG and DG).